Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter, Multinational, Active-controlled, Parallel-designed Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24months to 15yrs

NCT05613127 is registered in ClinicalTrials.gov with Boryung Biopharma Co., Ltd. as lead sponsor.

NCT NCT05613127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05613127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter, Multinational, Active-controlled, Parallel-designed Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24months to 15yrs
Lead sponsor
Boryung Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2022
Completion date
November 30, 2024
Enrollment
106 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hep a, hepatitis a